生物科技公司BioLife Solutions Inc.（BLFS）今日盘前大跌6.08%，主要受到其最新季度财报的影响。尽管公司的每股亏损优于预期，但收入同比大幅下滑引发了投资者的担忧。
根据公司发布的财报，截至3月31日的季度中，BioLife Solutions调整后每股亏损1美分，优于分析师预期的亏损5美分，也显著好于去年同期的亏损23美分。然而，公司营收为2394万美元，同比大幅下降24.5%，尽管高于分析师预期的2222万美元。本季度公司净亏损为44.8万美元。
值得注意的是，BioLife Solutions的股价在过去一个季度已下跌6.6%，今年迄今为止更是下跌了17.8%，显示出投资者对公司表现的持续担忧。尽管如此，华尔街分析师仍然对该公司保持乐观态度，目前对该股票的平均评级为"买入"，12个月目标价中位数为31.00美元。公司在医疗设备、用品和分销领域的表现仍受到关注，未来发展前景如何还有待进一步观察。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.